



What is required?

- 1 Fill out one medical history questionnaire.
- 2 Complete three short surveys about your experiences during your treatment.
- 3 Provide consent for researchers to collect information about your cancer diagnosis and treatment.

TrACER: Trial Assessing CSF prescribing Effectiveness and Risk (S1415CD)

is conducted by



SWOG is a worldwide network of researchers that design and conduct cancer clinical trials. To learn more, visit www.swog.org



Are you a patient receiving chemotherapy for breast, lung or colorectal cancer?

If so, you may be eligible to participate in this study.

TrACER: Trial Assessing CSF prescribing Effectiveness and Risk (S1415CD)

is conducted by



What is this research study?

This study examines how doctors prescribe medications known as colony stimulating factors (CSFs) to patients getting chemotherapy to help reduce the risk of serious infection. Some common brands of CSFs include Neulasta®, Neupogen®, Zarxio®, Granix®, ZarxioTM® and Leukine®.

This study will test if changing a clinic's prescription order system will help patients get CSFs when they need it and spare patients who do not need CSFs of costs and potential side effects from the medication.

Why is this study being done?

When prescribed as recommended, CSFs (colony stimulating factors) have clear benefits for patients. However, research has shown that CSFs are not always prescribed according to evidence-based national guidelines. This may be harming patients. Underuse of CSFs can raise a patient's risk for infection. Overuse or unneeded use can lead to side effects like bone and muscle pain but give no benefit.


Your participation will help researchers better understand patient experiences using CSFs—including the symptoms, side effects, and costs of medications—with the goal of improving care and patient outcomes in the future.

How will participation affect me?

- This study does not involve any experimental treatments.
- There is a small risk you may feel uncomfortable being asked about your functional, emotional and social well-being on study questionnaires.
- There are no added costs to you for participating in this study. You will not need to make any special trips to the clinic, and you will not be asked to undergo any extra treatments, tests, or procedures.
- If you choose to participate, your care and treatment will not be affected in any way. Because the study is voluntary, you have the option to drop out any time without providing an explanation.

Who is participating?

The oncologists at your clinic, along with those from 39 other practices in the US, are participating in this study. We are recruiting about 90 patients from each location.



Questions? Interested in learning more?

Contact:

A description of TrACER: Trial Assessing CSF prescribing Effectiveness and Risk (S1415CD) is also available on <http://www.ClinicalTrials.gov>.